Developing RNase P Ribozymes for Therapy of Herpes Simplex Virus 1
Keywords:
Quality improvement, brazil, organ transplantation, management program, PAT-MA, health systems, Maranh, pulmonary hypertension., Chronic thromboembolic pulmonary hypertension, Thrombendarterectomy, Pulmonary vascular resistance, Long-term medical history., HIV, cervical cancer, Screening, CIN, HPV, Togo., Tokophobia, Developmental trauma, Cognitive-behavioral therapy, Reproductive mental health, Cultural psychiatry, Enteropathy, CCECAI score, Immunohistochemistry, CD3+positive cellsAbstract
RNase P ribozymes, derived from the M1 RNA of Escherichiacoli, have shown great promise as a novel nucleic acid-based gene interference approach to modulate gene expression. When the M1 RNA component of RNase P is covalently linked with a guide sequence (GS), it can be engineered into a sequence-specific endonuclease M1GS ribozyme. As the GS base-pairs with target mRNAs, it forms a structure that mimics a pre-tRNA-like substrate, allowing for M1 RNA’s structure-based recognition mechanism. These M1GS constructs function catalytically and irreversibly, capable of cleaving target mRNA substrates without relying on host proteins. M1GS activity enhancement has been achieved through an in vitro selection process that introduced mutations in the catalytic core of M1 RNA. This process generated ribozyme variants with greatly improved cleavage efficiency and substrate affinity. M1GS ribozymes have been successful in inhibiting herpes simplex virus 1 (HSV-1) by targeting genes critical for viral infection. HSV-1 is the causative agent of cold sores and may lead to severe morbidity and mortality in neonates and immunocompromised individuals. HSV-1 establishes lifelong latent infection, and novel anti-HSV-1 strategies are needed to block and eliminate viral latency and reactivation. Using HSV-1 infection as an example, this review will summarize the function of RNase P and its catalytic RNA, the enhancement and engineering of M1GS ribozymes, and their potential as a gene-targeting agent for therapeutic applications against HSV-1.
References
L. J. Scherer, J. J. Rossi (2003) Approaches for the sequence-specific knockdown of mRNA. 21(12), 1457-65.
A. Sparmann, J. Vogel (2023) RNA-based medicine: from molecular mechanisms to therapy. 42(21), e114760.
J. Y. Wang, J. A. Doudna (2023) CRISPR technology: A decade of genome editing is only the beginning. 379(6629), eadd8643.
A. Smith, I. Zhang, P. Trang, F. Liu (2024) Engineering of RNase P Ribozymes for Therapy against Human Cytomegalovirus Infection. 16(8).
N. Sarver, E. M. Cantin, P. S. Chang, J. A. Zaia, P. A. Ladne, D. A. Stephens, J. J. Rossi (1990) Ribozymes as Potential Anti-HIV-1 Therapeutic Agents. 247(4947), 1222-1225.
M. Yu, J. Ojwang, O. Yamada, A. Hampel, J. Rapapport, D. Looney, F. Wong-Staal (1993) A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. 90(13), 6340-6344.
L. Aagaard, J. J. Rossi (2007) RNAi therapeutics: principles, prospects and challenges. 59(2-3), 75-86.
D. R. Caffrey, J. Zhao, Z. Song, M. E. Schaffer, S. A. Haney, R. R. Subramanian, A. B. Seymour, J. D. Hughes (2011) siRNA off-target effects can be reduced at concentrations that match their individual potency. 6(7), e21503.
P. C. Scacheri, O. Rozenblatt-Rosen, N. J. Caplen, T. G. Wolfsberg, L. Umayam, J. C. Lee, C. M. Hughes, K. S. Shanmugam, A. Bhattacharjee, M. Meyerson, F. S. Collins (2004) Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. 101(7), 1892-7.
C. Guo, X. Ma, F. Gao, Y. Guo (2023) Off-target effects in CRISPR/Cas9 gene editing. 11, 1143157.
V. Gopalan, A. Vioque, S. Altman (2002) RNase P: variations and uses. 277, 6759-6762.
L. A. Kirsebom, F. Liu, W. H. McClain (2024) The discovery of a catalytic RNA within RNase P and its legacy. 300(6), 107318.
F. Liu, S. Altman (1995) Inhibition of viral gene expression by the catalytic RNA subunit of RNase P from Escherichia coli. 9(4), 471-80.
N. Jarrous, F. Liu (2023) Human RNase P: overview of a ribonuclease of interrelated molecular networks and gene-targeting systems. 29(3), 300-307.
A. R. Chamberlain, L. Huynh, W. Huang, D. J. Taylor, M. E. Harris (2024) The specificity landscape of bacterial ribonuclease P. 300(1), 105498.
B. Zhou, F. Wan, K. X. Lei, P. Lan, J. Wu, M. Lei (2024) Coevolution of RNA and protein subunits in RNase P and RNase MRP, two RNA processing enzymes. 300(3), 105729.
D. Rafael, E. Tomer, O. Kobiler (2022) A Single Herpes Simplex Virus 1 Genome Reactivates from Individual Cells. 10(4), e0114422.
D. M. Knipe, E. E. Heldwein, I. J. Mohr, C. N. Sodroski (2021) Herpes Simplex Viruses: Mechanisms of Lytic and Latent Infection. 1, 235-296.
R. J. Whitley, C. Johnston (2021) Herpes Simplex Viruses: Pathogenesis and Clinical Insights. 1, 237-323.
B. Roizman, D. M. Knipe, R. J. Whitley (2007) Herpes Simplex Viruses. 2503-2601.
J. Piret, G. Boivin (2011) Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. 55(2), 459-72.
Y. Xie, L. Wu, M. Wang, A. Cheng, Q. Yang, Y. Wu, R. Jia, D. Zhu, X. Zhao, S. Chen, M. Liu, S. Zhang, Y. Wang, Z. Xu, Z. Chen, L. Zhu, Q. Luo, Y. Liu, Y. Yu, L. Zhang, X. Chen (2019) Alpha-Herpesvirus Thymidine Kinase Genes Mediate Viral Virulence and Are Potential Therapeutic Targets. 10, 941.
E. Brookes, A. Riccio (2019) Location, location, location: nuclear structure regulates gene expression in neurons. 59, 16-25.
A. R. Cliffe, D. A. Garber, D. M. Knipe (2009) Transcription of the herpes simplex virus latency-associated transcript promotes the formation of facultative heterochromatin on lytic promoters. 83(16), 8182-90.
K. Tanaka, Y. Kim, M. Roche, S. R. Lewin (2022) The role of latency reversal in HIV cure strategies. 51(5), 278-283.
F. R. Van Diemen, E. M. Kruse, M. J. Hooykaas, C. E. Bruggeling, A. C. Schürch, P. M. van Ham, S. M. Imhof, M. Nijhuis, E. J. Wiertz, R. J. Lebbink (2016) CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. 12((6)), e1005701.
M. Aubert, A. K. Haick, D. E. Strongin, L. M. Klouser, M. A. Loprieno, L. Stensland, T. K. Santo, M.-L. Huang, O. Hyrien, D. Stone, K. R. Jerome (2024) Gene editing for latent herpes simplex virus infection reduces viral load and shedding in vivo. 15((1)), 4018.
A. R. Cliffe, J. H. Arbuckle, J. L. Vogel, M. J. Geden, S. B. Rothbart, C. L. Cusack, B. D. Strahl, T. M. Kristie, M. Deshmukh (2015) Neuronal Stress Pathway Mediating a Histone Methyl/Phospho Switch Is Required for Herpes Simplex Virus Reactivation. 18((6)), 649-58.
D. N. Frank, N. R. Pace (1998) Ribonuclease P: unity and diversity in a tRNA processing ribozyme. 67, 153-80.
S. Xiao, F. Scott, C. A. Fierke, D. R. Engelke (2002) Eukaryotic ribonuclease P: a plurality of ribonucleoprotein enzymes. 71, 165-89.
Y. Li, S. Altman (2004) Polarity effects in the lactose operon of Escherichia coli. 339((1)), 31-9.
P. Alifano, F. Rivellini, C. Piscitelli, C. M. Arraiano, C. B. Bruni, M. S. Carlomagno (1994) Ribonuclease E provides substrates for ribonuclease P-dependent processing of a polycistronic mRNA. 8((24)), 3021-31.
S. Altman, D. Wesolowski, C. Guerrier-Takada, Y. Li (2005) RNase P cleaves transient structures in some riboswitches. 102((32)), 11284-9.
K. A. Peck-Miller, S. Altman (1991) Kinetics of the processing of the precursor to 4.5 S RNA, a naturally occurring substrate for RNase P from Escherichia coli. 221((1)), 1-5.
C. Guerrier-Takada, K. Gardiner, T. Marsh, N. Pace, S. Altman (1983) The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. 35((3 Pt 2)), 849-57.
S. M. Crary, S. Niranjanakumari, C. A. Fierke (1998) The protein component of Bacillus subtilis ribonuclease P increases catalytic efficiency by enhancing interactions with the 5' leader sequence of pre-tRNAAsp. 37((26)), 9409-16.
V. Gopalan, A. D. Baxevanis, D. Landsman, S. Altman (1997) Analysis of the functional role of conserved residues in the protein subunit of ribonuclease P from Escherichia coli. 267(4), 818-29.
J. Hsieh, A. J. Andrews, C. A. Fierke (2004) Roles of protein subunits in RNA-protein complexes: lessons from ribonuclease P. 73(1), 79-89.
J. J. Kim, A. F. Kilani, X. Zhan, S. Altman, F. Liu (1997) The protein cofactor allows the sequence of an RNase P ribozyme to diversify by maintaining the catalytically active structure of the enzyme. 3(6), 613-23.
J. C. Kurz, S. Niranjanakumari, C. A. Fierke (1998) Protein component of Bacillus subtilis RNase P specifically enhances the affinity for precursor-tRNAAsp. 37(8), 2393-400.
S. Niranjanakumari, T. Stams, S. M. Crary, D. W. Christianson, C. A. Fierke (1998) Protein component of the ribozyme ribonuclease P alters substrate recognition by directly contacting precursor tRNA. 95(26), 15212-7.
E. Westhof, D. Wesolowski, S. Altman (1996) Mapping in three dimensions of regions in a catalytic RNA protected from attack by an Fe(II)-EDTA reagent. 258(4), 600-13.
J. C. Kurz, C. A. Fierke (2002) The affinity of magnesium binding sites in the Bacillus subtilis RNase P x pre-tRNA complex is enhanced by the protein subunit. 41(30), 9545-58.
N. J. Reiter, A. Osterman, A. Torres-Larios, K. K. Swinger, T. Pan, A. Mondragón (2010) Structure of a bacterial ribonuclease P holoenzyme in complex with tRNA. 468(7325), 784-9.
J. Zhu, W. Huang, J. Zhao, L. Huynh, D. J. Taylor, M. E. Harris (2022) Structural and mechanistic basis for recognition of alternative tRNA precursor substrates by bacterial ribonuclease P. 13(1), 5120.
N. Jarrous, R. Reiner, D. Wesolowski, H. Mann, C. Guerrier-Takada, S. Altman (2001) Function and subnuclear distribution of Rpp21, a protein subunit of the human ribonucleoprotein ribonuclease P. 7(8), 1153-64.
K. Kim, F. Liu (2007) Inhibition of gene expression in human cells using RNase P-derived ribozymes and external guide sequences. 1769(11-12), 603-12.
A. C. Forster, S. Altman (1990) External guide sequences for an RNA enzyme. 249(4970), 783-6.
W. H. McClain, C. Guerrier-Takada, S. Altman (1987) Model substrates for an RNA enzyme. 238, 527-30.
A. Garg, D. Wesolowski, D. Alonso, K. W. Deitsch, C. Ben Mamoun, S. Altman (2015) Targeting protein translation, RNA splicing, and degradation by morpholino-based conjugates in Plasmodium falciparum. 112(38), 11935-40.
C. Guerrier-Takada, Y. Li, S. Altman (1995) Artificial regulation of gene expression in Escherichia coli by RNase P. 92(24), 11115-11119.
D. Wesolowski, D. Alonso, S. Altman (2013) Combined effect of a peptide–morpholino oligonucleotide conjugate and a cell-penetrating peptide as an antibiotic. 110(21), 8686-8689.
J. McKinney, C. Guerrier-Takada, D. Wesolowski, S. Altman (2001) Inhibition of Escherichia coli viability by external guide sequences complementary to two essential genes. 98(12), 6605-6610.
J. S. McKinney, H. Zhang, T. Kubori, J. E. Galán, S. Altman (2004) Disruption of type III secretion in Salmonella enterica serovar Typhimurium by external guide sequences. 32(2), 848-854.
D. Wesolowski, H. S. Tae, N. Gandotra, P. Llopis, N. Shen, S. Altman (2011) Basic peptide-morpholino oligomer conjugate that is very effective in killing bacteria by gene-specific and nonspecific modes. 108(40), 16582-16587.
Y. Yuan, E. S. Hwang, S. Altman (1992) Targeted cleavage of mRNA by human RNase P. 89(17), 8006-8010.
C. Guerrier-Takada, R. Salavati, S. Altman (1997) Phenotypic conversion of drug-resistant bacteria to drug sensitivity. 94(16), 8468-72.
Q. Deng, Y. Liu, X. Li, B. Yan, X. Sun, W. Tang, P. Trang, Z. Yang, H. Gong, Y. Wang, J. Lu, J. Chen, C. Xia, X. Xing, S. Lu, F. Liu (2019) Inhibition of human cytomegalovirus major capsid protein expression and replication by ribonuclease P-associated external guide sequences. 25(5), 645-655.
D. Kawa, J. Wang, Y. Yuan, F. Liu (1998) Inhibition of viral gene expression by human ribonuclease P. 4(11), 1397-406.
G. Kraus, R. Geffin, G. Spruill, A. K. Young, R. Seivright, D. Cardona, J. Burzawa, H. J. Hnatyszyn (2002) Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences. 99(6), 3406-3411.
C. Xia, Y.-C. Chen, H. Gong, W. Zeng, G.-P. Vu, P. Trang, S. Lu, J. Wu, F. Liu (2013) Inhibition of Hepatitis B Virus Gene Expression and Replication by Ribonuclease P. 21(5), 995-1003.
J. Zhu, P. Trang, K. Kim, T. Zhou, H. Deng, F. Liu (2004) Effective inhibition of Rta expression and lytic replication of Kaposi's sarcoma-associated herpesvirus by human RNase P. 101(24), 9073-9078.
D. Plehn-Dujowich, S. Altman (1998) Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonuclease P. 95(13), 7327-32.
M. Ma, L. Benimetskaya, I. Lebedeva, J. Dignam, G. Takle, C. A. Stein (2000) Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences. 18(1), 58-61.
Y. Li, C. Guerrier-Takada, S. Altman (1992) Targeted cleavage of mRNA in vitro by RNase P from Escherichia coli. 89(8), 3185-3189.
F. Liu, S. Altman (1996) Requirements for Cleavage by a Modified RNase P of a Small Model Substrate. 24(14), 2690-2696.
P. Trang, J. Lee, A. F. Kilani, J. Kim, F. Liu (2001) Effective inhibition of herpes simplex virus 1 gene expression and growth by engineered RNase P ribozyme. 29(24), 5071-8.
H. Mann, Y. Ben-Asouli, A. Schein, S. Moussa, N. Jarrous (2003) Eukaryotic RNase P: Role of RNA and Protein Subunits of a Primordial Catalytic Ribonucleoprotein in RNA-Based Catalysis. 12(4), 925-935.
E. Sharin, A. Schein, H. Mann, Y. Ben-Asouli, N. Jarrous (2005) RNase P: role of distinct protein cofactors in tRNA substrate recognition and RNA-based catalysis. 33(16), 5120-5132.
A. F. Kilani, P. Trang, S. Jo, A. Hsu, J. Kim, E. Nepomuceno, K. Liou, F. Liu (2000) RNase P ribozymes selected in vitro to cleave a viral mRNA effectively inhibit its expression in cell culture. 275(14), 10611-22.
H. Zou, J. Lee, A. F. Kilani, K. Kim, P. Trang, J. Kim, F. Liu (2004) Engineered RNase P ribozymes increase their cleavage activities and efficacies in inhibiting viral gene expression in cells by enhancing the rate of cleavage and binding of the target mRNA. 279(31), 32063-70.
A. F. Kilani, F. Liu (1999) UV cross-link mapping of the substrate-binding site of an RNase P ribozyme to a target mRNA sequence. 5(9), 1235-47.
P. Trang, A. Kilani, J. Kim, F. Liu (2000) A ribozyme derived from the catalytic subunit of RNase P from Escherichia coli is highly effective in inhibiting replication of herpes simplex virus 1. 301(4), 817-26.
C. A. Stein, Y. C. Cheng (1993) Antisense oligonucleotides as therapeutic agents--is the bullet really magical?. 261(5124), 1004-12.
C. Cobaleda, I. Sánchez-García (2000) In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment. 95(3), 731-7.
S. Verma, F. Eckstein (1998) Modified oligonucleotides: synthesis and strategy for users. 67, 99-134.
J. C. Burnett, J. J. Rossi (2012) RNA-based therapeutics: current progress and future prospects. 19(1), 60-71.
Y. Bai, H. Gong, H. Li, G.-P. Vu, S. Lu, F. Liu (2011) Oral delivery of RNase P ribozymes by Salmonella inhibits viral infection in mice. 108(8), 3222-3227.
Y. Bai, H. Li, G.-P. Vu, H. Gong, S. Umamoto, T. Zhou, S. Lu, F. Liu (2010) Salmonella-mediated delivery of RNase P-based ribozymes for inhibition of viral gene expression and replication in human cells. 107(16), 7269-7274.
X. Jiang, H. Gong, Y.-C. Chen, G.-P. Vu, P. Trang, C.-Y. Zhang, S. Lu, F. Liu (2012) Effective inhibition of cytomegalovirus infection by external guide sequences in mice. 109(32), 13070-13075.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.
